Evaxion reports new Phase 2 data for EVX-01 showing ex vivo detection of neoantigen-specific T cells

Evaxion released new Phase 2 data for its personalized cancer vaccine EVX-01, showing detection of neoantigen-specific T cells directly ex vivo, which the company says confirms strong immune responses and underlines the predictive performance of its AI-Immunology platform.

Detected & updated continuously · Source: Nebula